

# Monica Girotra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7959159/publications.pdf>

Version: 2024-02-01

13  
papers

857  
citations

759233

12  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended Survival After Surgical Resection for Pituitary Metastases: Clinical Features, Management, and Outcomes of Metastatic Disease to the Sella. <i>Oncologist</i> , 2020, 25, e789-e797.	3.7	19
2	Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience. <i>Diabetes Care</i> , 2020, 43, 3106-3109.	8.6	28
3	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	2.2	20
4	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020, 28, 6175-6181.	2.2	15
5	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	2.2	11
6	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	2.2	28
7	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020, 28, 6111-6117.	2.2	22
8	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	2.2	14
9	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <i>British Journal of Anaesthesia</i> , 2020, 124, 251-260.	3.4	35
10	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	2.9	92
11	Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	9.6	515
12	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017, 7, 32-37.	2.4	21
13	IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. <i>International Journal of Cancer</i> , 2000, 87, 824-828.	5.1	37